Published in J Biol Chem on August 29, 1997
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. J Physiol (2006) 1.71
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol (2007) 1.49
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol (1999) 1.37
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest (2003) 1.26
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol (2000) 1.25
Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (2001) 1.22
Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol (2007) 1.20
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol (2010) 1.19
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J (2000) 1.19
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem (2010) 1.15
Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br J Pharmacol (1999) 1.14
Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br J Pharmacol (1999) 1.11
The C terminus of the Saccharomyces cerevisiae alpha-factor receptor contributes to the formation of preactivation complexes with its cognate G protein. Mol Cell Biol (2000) 1.10
CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol Pharmacol (2007) 1.09
Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry (2006) 1.09
Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther (2010) 1.09
Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem J (2001) 1.06
Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol (2007) 1.06
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 1.05
Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol (2011) 1.05
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol (1999) 1.03
Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus (2010) 1.03
Efficacy in CB1 receptor-mediated signal transduction. Br J Pharmacol (2004) 1.01
Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets (2009) 0.99
Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol (2010) 0.99
Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol (2001) 0.97
Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action. Br J Pharmacol (2013) 0.97
Coupling mode of receptors and G proteins. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.96
Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. J Med Chem (2012) 0.96
CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) (2004) 0.96
Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol (2007) 0.96
Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes (2009) 0.95
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem (2010) 0.95
Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br J Pharmacol (2012) 0.94
Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorg Med Chem Lett (2011) 0.93
Third-party bioluminescence resonance energy transfer indicates constitutive association of membrane proteins: application to class a g-protein-coupled receptors and g-proteins. Biophys J (2010) 0.93
Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells. Br J Pharmacol (2012) 0.92
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-3beta/beta-catenin signaling. J Biol Chem (2010) 0.92
Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release. J Neurosci (2015) 0.91
The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol (2011) 0.91
Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol (2000) 0.90
Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br J Pharmacol (2004) 0.90
Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. J Biol Chem (2010) 0.90
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol (2008) 0.89
The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A (2004) 0.88
Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica (2011) 0.88
The vital role of constitutive GPCR activity in the mesolimbic dopamine system. Transl Psychiatry (2014) 0.87
Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol (2000) 0.86
A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation. Brain Res (2006) 0.86
Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol (2001) 0.85
Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol (2010) 0.84
Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol (2006) 0.83
Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? Curr Neuropharmacol (2007) 0.82
Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation. J Biol Chem (2011) 0.82
Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci (2013) 0.82
A3 adenosine and CB1 receptors activate a PKC-sensitive Cl- current in human nonpigmented ciliary epithelial cells via a G beta gamma-coupled MAPK signaling pathway. Br J Pharmacol (2003) 0.81
Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. Sci Rep (2016) 0.81
Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) (2012) 0.80
Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo. Synapse (2009) 0.80
Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling. Br J Pharmacol (2012) 0.80
The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail. J Neurochem (2011) 0.79
Peripherally selective diphenyl purine antagonist of the CB1 receptor. J Med Chem (2013) 0.79
Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol (2005) 0.79
Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Neuropsychopharmacology (2017) 0.78
Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro. Cell Mol Neurobiol (2010) 0.78
Understanding functional residues of the cannabinoid CB1. Curr Top Med Chem (2010) 0.78
CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell (2016) 0.78
Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Front Cell Neurosci (2017) 0.77
Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Curr Neuropharmacol (2010) 0.77
Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. PLoS One (2016) 0.77
Honey Bee Allatostatins Target Galanin/Somatostatin-Like Receptors and Modulate Learning: A Conserved Function? PLoS One (2016) 0.77
Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods Enzymol (2010) 0.76
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther (2015) 0.76
CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res (2016) 0.75
Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro. PLoS One (2016) 0.75
Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk. Sci Rep (2016) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun (1990) 4.46
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int (2000) 4.43
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther (1998) 3.20
Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost (2000) 2.45
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost (1994) 2.05
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control. J Biol Chem (1992) 1.92
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem (1998) 1.84
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett (1993) 1.62
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett (1997) 1.57
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci (1992) 1.56
Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol (1992) 1.56
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest (1994) 1.50
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.43
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) (1996) 1.40
Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays. J Biol Chem (2000) 1.37
The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol (1994) 1.36
Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature (1981) 1.35
An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest (1995) 1.33
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett (1996) 1.32
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol (1994) 1.27
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem (1984) 1.24
Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem Biophys Res Commun (1990) 1.24
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 1.21
P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun (2001) 1.20
In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol (1998) 1.18
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost (1996) 1.17
Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull (1987) 1.17
Induction of CD95 (Fas) and apoptosis in respiratory epithelial cell cultures following respiratory syncytial virus infection. Virology (1999) 1.16
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry (2004) 1.16
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
The 2'-5' oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol (2000) 1.14
Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor. Biochim Biophys Acta (2001) 1.14
Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther (1998) 1.14
Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood (1998) 1.13
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina. Brain Res Mol Brain Res (2001) 1.13
Mutations of the p53 gene in human myeloma cell lines. Oncogene (1992) 1.13
Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem (1986) 1.13
A probable linkage between familial Paget's disease and the HLA loci. Aust N Z J Med (1982) 1.12
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev (1982) 1.11
Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem (2000) 1.10
Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett (1995) 1.10
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10